Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) today jointly announce the start of a long-term ...

Boehringer Ingelheim and MTM Vision join forces to combat vision loss from diabetes: Ingelheim, Germany Wednesday, November 13, 2024, 10:00 Hrs [IST] Boehringer Ingelheim and the ...

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

Ingelheim, Germany and Ann Arbor, MI, USA, November 12, 2024 – Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) today jointly announce the start of a long-term ...

Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

The Middle East Veterinary Vaccine Market is poised for steady growth, with a projected market size of USD 627.1 million in 2023. The market is expected to expand at a CAGR of 4% through 2033, ...

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

People with chronic kidney disease, Type 2 diabetes or both were predicted to have elevated cardiovascular disease (CVD) risk 8 to 28 years sooner than someone without those conditions, according to a ...

Recent developments driving growth in this area make the advanced, AI-supported digitization of pharma pipelines inevitable.